Arrowhead Pharmaceuticals Statistics

Total Valuation

Arrowhead Pharmaceuticals has a market cap or net worth of GBP 1.99 billion. The enterprise value is 2.14 billion.

Market Cap	1.99B
Enterprise Value	2.14B

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+12.21%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	110.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	15.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.78
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.74

Financial Position

The company has a current ratio of 6.74, with a Debt / Equity ratio of 4.46.

Current Ratio	6.74
Quick Ratio	6.57
Debt / Equity	4.46
Debt / EBITDA	n/a
Debt / FCF	-1.41
Interest Coverage	-18.58

Financial Efficiency

Return on equity (ROE) is -254.98% and return on invested capital (ROIC) is -43.85%.

Return on Equity (ROE)	-254.98%
Return on Assets (ROA)	-39.43%
Return on Capital (ROIC)	-43.85%
Revenue Per Employee	4,350
Profits Per Employee	-734,453
Employee Count	609
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.86% in the last 52 weeks. The beta is 0.93, so Arrowhead Pharmaceuticals's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-41.86%
50-Day Moving Average	20.85
200-Day Moving Average	22.89
Relative Strength Index (RSI)	49.00
Average Volume (20 Days)	2,753

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.55

Income Statement

In the last 12 months, Arrowhead Pharmaceuticals had revenue of GBP 2.65 million and -447.28 million in losses. Loss per share was -3.73.

Revenue	2.65M
Gross Profit	2.65M
Operating Income	-448.47M
Pretax Income	-456.96M
Net Income	-447.28M
EBITDA	-434.59M
EBIT	-448.47M
Loss Per Share	-3.73

Full Income Statement

Balance Sheet

The company has 505.45 million in cash and 635.61 million in debt, giving a net cash position of -130.16 million.

Cash & Cash Equivalents	505.45M
Total Debt	635.61M
Net Cash	-130.16M
Net Cash Per Share	n/a
Equity (Book Value)	142.55M
Book Value Per Share	1.11
Working Capital	441.92M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -345.33 million and capital expenditures -105.55 million, giving a free cash flow of -450.88 million.

Operating Cash Flow	-345.33M
Capital Expenditures	-105.55M
Free Cash Flow	-450.88M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-16,927.06%
Pretax Margin	-17,247.54%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Arrowhead Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.21%
Shareholder Yield	-12.21%
Earnings Yield	-22.46%
FCF Yield	-22.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Arrowhead Pharmaceuticals has an Altman Z-Score of -1.08. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.08
Piotroski F-Score	n/a